Monjuvi Combo Reduces Progression Risk in Follicular Lymphoma
Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, according to Dr. Christina Poh.
Understanding the Science Behind the Monjuvi Approval in Lymphoma
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent approval for follicular lymphoma.
Rapid Developments to Enhance Patient Experience in GU Cancer
New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while personalizing patient outcomes.
First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.
An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Active Surveillance Viable Option for Some With Prostate Cancer
Patients with favorable-risk prostate cancer “should be aware that they don't need treatment right away,” one expert said.
Differentiating Muscle-Invasive, Non-Muscle-Invasive Bladder Cancer
When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer.
Patients With MPN-Related Fatigue ‘Know Their Bodies Very Well’
It’s key for patients with MPN-related fatigue to communicate changes they feel, especially as they “know their bodies very well,” a nurse told CURE®.
